Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $39.10 | Total: $195.50 |
| 1 | 10 | $33.12 | Total: $331.20 |
| 1 | 25 | $28.06 | Total: $701.50 |
| 1 | 50 | $23.92 | Total: $1,196.00 |
| 1 | 100 | $20.70 | Total: $2,070.00 |
Overview
LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the ?-secretase protein.
Chemical Properties
| Molecular Formula | C23H27N3O4 |
| Molecular Weight | 409.48 |
| CAS Numbers | 209984-68-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N(C([C@@H](NC([C@H](C(C)C)O)=O)C)=O)[C@H]1C=2C(C=3C(N(C)C1=O)=CC=CC3)=CC=CC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer[J]. European Journal of Cancer, 2016, 56.